Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 May 2013 Results presented at the 32nd Annual Scientific Meeting of the American Pain Society.
- 16 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 19 Jul 2010 Status changed from recruiting to suspended, based on a Pfizer media release. Adverse events were noted tanezumab recipients with osteoarthritis, and the FDA requested suspension based on the potential for adverse events in other patient populations.